{"id":825025,"date":"2025-03-12T16:46:20","date_gmt":"2025-03-12T20:46:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/"},"modified":"2025-03-12T16:46:20","modified_gmt":"2025-03-12T20:46:20","slug":"avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/","title":{"rendered":"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, <span class=\"xn-org\">University of Arkansas<\/span> for Medical Sciences and Arkansas Children&#8217;s Hospital and EXPLORE44<\/i><br \/>\n        <sup>\u00ae<\/sup><br \/>\n        <i> trial investigator, will present topline del-zota data from Phase 1\/2 EXPLORE44<\/i>\u00a0<i>trial at 2025 MDA Clinical &amp; Scientific Conference in <span class=\"xn-location\">Dallas, Texas<\/span><\/i><\/p>\n<p class=\"prntac\">\n        <i>Avidity to host investor and analyst webcast event <span class=\"xn-chron\">March 17, 2025<\/span>, at <span class=\"xn-chron\">8:00 a.m. ET<\/span><\/i>\n      <\/p>\n<p class=\"prntac\">\n        <i>Key opinion leaders to participate in Avidity sponsored industry forum event &#8220;Advancing RNA Therapeutics&#8221;, <span class=\"xn-chron\">March 17, 2025<\/span>, at <span class=\"xn-chron\">7:00 a.m. CT<\/span>\/<span class=\"xn-chron\">8:00 a.m. ET<\/span><\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 12, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that the company will be presenting one oral and two poster presentations at the 2025 MDA Clinical &amp; Scientific Conference (MDA) in <span class=\"xn-location\">Dallas, Texas<\/span>, being held <span class=\"xn-chron\">March 16-19, 2025<\/span> and will host an investor and analyst webcast event on <span class=\"xn-chron\">March 17, 2025<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg\" title=\"(PRNewsfoto\/Avidity Biosciences, Inc.)\" alt=\"(PRNewsfoto\/Avidity Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b><br \/>\n          <u>2025 MDA Clinical &amp; Scientific Conference <\/u><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <u>Oral &amp; Poster Presentations<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <i><br \/>\n          <span class=\"xn-chron\">March 19, 2025<\/span>: <span class=\"xn-chron\">9:00 a.m.<\/span> \u2013 9:15 a.m.\u00a0CT <\/i>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1\/2 study in patients with DMD44 (<i>oral presentation<\/i>)<\/b><br \/>\n          <\/p>\n<p>Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, <span class=\"xn-org\">University of Arkansas<\/span> for Medical Sciences and Arkansas Children&#8217;s Hospital, and EXPLORE44<sup>\u00ae<\/sup> trial investigator, will present topline del-zota data from Avidity&#8217;s Phase 1\/2 EXPLORE44 trial for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44).<\/p>\n<\/li>\n<\/ul>\n<p>\n        <i><br \/>\n          <span class=\"xn-chron\">March 16-18, 2025<\/span>: <span class=\"xn-chron\">6:00 p.m.<\/span> \u2013 8:00 p.m.\u00a0CT <\/i>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1\/2 study in patients with DMD44 (<i>poster presentation<\/i>)<\/p>\n<p><\/b>\n        <\/li>\n<li>\n          <b>Phase 3, randomized, global study assessing efficacy and safety of\u00a0del-desiran for the treatment of myotonic dystrophy type 1: HARBOR\u2122 trial design (<i>poster presentation<\/i>)<\/b>\n        <\/li>\n<\/ul>\n<p>The presentation and posters will be available on the <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4378952-1&amp;h=3296706510&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3669169-1%26h%3D3032699912%26u%3Dhttps%253A%252F%252Fwww.aviditybiosciences.com%252Fplatform%252Fpublications%252F%26a%3Dpublications%2Bpage&amp;a=publications+page\" target=\"_blank\" rel=\"nofollow\">publications page<\/a> of Avidity&#8217;s website at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4378952-1&amp;h=1397469015&amp;u=https%3A%2F%2Fwww.aviditybiosciences.com%2F&amp;a=https%3A%2F%2Fwww.aviditybiosciences.com\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.aviditybiosciences.com<\/a> following the conference.<\/p>\n<p>\n        <b><br \/>\n          <u>Avidity Sponsored Industry Forum Breakfast Event During MDA Conference<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>On <span class=\"xn-chron\">March 17, 2025<\/span>, <span class=\"xn-chron\">7:00 a.m. CT<\/span>, <span class=\"xn-person\">Mike Flanagan<\/span>, PhD, Chief Scientific Officer at Avidity, will host an industry forum breakfast titled &#8220;<i>Advancing RNA Therapeutics: Exploring Antibody Oligonucleotide Conjugates (AOCs) for Rare Neuromuscular Diseases.<\/i>&#8221; Dr. Flanagan will be joined by guest speaker, <span class=\"xn-person\">Nicholas E. Johnson<\/span>, MD, MSCI, FAAN, Vice Chair for Research, Department of Neurology, <span class=\"xn-org\">Virginia Commonwealth University<\/span>, and will also be joined by <span class=\"xn-person\">Jeffrey M. Statland<\/span>, MD, Professor of Neurology, <span class=\"xn-org\">University of Kansas Medical Center<\/span>, and <span class=\"xn-person\">Johanna Hamel<\/span>, MD, Associate Professor of Neurology, Psychology and Laboratory Medicine, <span class=\"xn-org\">University of Rochester<\/span> to take part in a Q&amp;A session. Participation will be open to all MDA Conference registered attendees.<\/p>\n<p>\n        <b><br \/>\n          <u>Avidity Investor and Analyst Webcast<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <span>Avidity management will be joined by <span class=\"xn-person\">Kevin Flanigan<\/span>, MD, <\/span><br \/>\n        <span>Robert F. and Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular<\/span><br \/>\n        <span> Research <\/span><br \/>\n        <span>at<\/span><br \/>\n        <span> Nationwide <\/span><br \/>\n        <span>Children&#8217;s<\/span><br \/>\n        <span> Hospital<\/span><br \/>\n        <span>, and Professor of Pediatrics and Neurology at the<\/span><br \/>\n        <span><br \/>\n          <span class=\"xn-location\">Ohio<\/span><br \/>\n        <\/span><br \/>\n        <span> State University College of Medicine<\/span><br \/>\n        <span>, on <span class=\"xn-chron\">March 17, 2025<\/span>, at <span class=\"xn-chron\">8:00 a.m. ET<\/span> for a live video webcast to discuss del-zota topline data from the EXPLORE44 trial, which will be available\u00a0<\/span>on the company&#8217;s website at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4378952-1&amp;h=1694711688&amp;u=https%3A%2F%2Faviditybiosciences.investorroom.com%2Fevents-and-presentations&amp;a=https%3A%2F%2Faviditybiosciences.investorroom.com%2Fevents-and-presentations\" target=\"_blank\" rel=\"nofollow\">https:\/\/aviditybiosciences.investorroom.com\/events-and-presentations<\/a>.\u00a0<\/p>\n<p>\n        <b>About Avidity<\/b><br \/>\n        <br \/>Avidity Biosciences, Inc.&#8217;s mission is to profoundly improve people&#8217;s lives by delivering a new class of RNA therapeutics &#8211; Antibody Oligonucleotide Conjugates (AOCs\u2122). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in\u202fSan Diego, CA.\u202fFor more information about our AOC platform, clinical development pipeline and people, please visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4378952-1&amp;h=2956003362&amp;u=https%3A%2F%2Fwww.aviditybiosciences.com%2F&amp;a=www.aviditybiosciences.com\" target=\"_blank\" rel=\"nofollow\">www.aviditybiosciences.com<\/a>\u00a0and engage with us on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4378952-1&amp;h=1609701898&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Favidity-biosciences-llc%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4378952-1&amp;h=2290903174&amp;u=https%3A%2F%2Fx.com%2Faviditybio&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>.<\/p>\n<p>\n        <b>Investor Contact:<\/b><br \/>\n        <br \/>Kat Lange<br \/>(619) 837-5014<br \/><a href=\"mailto:investors@aviditybio.com\" target=\"_blank\" rel=\"nofollow\">investors@aviditybio.com<\/a><\/p>\n<p>\n        <b>Media Contact:<\/b><br \/>\n        <br \/>(619) 837-5016<br \/><a href=\"mailto:media@aviditybio.com\" target=\"_blank\" rel=\"nofollow\">media@aviditybio.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA36682&amp;sd=2025-03-12\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical--scientific-conference-302400330.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical&#8211;scientific-conference-302400330.html<\/a><\/p>\n<p>SOURCE  Avidity Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA36682&amp;Transmission_Id=202503121605PR_NEWS_USPR_____LA36682&amp;DateId=20250312\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children&#8217;s Hospital and EXPLORE44 \u00ae trial investigator, will present topline del-zota data from Phase 1\/2 EXPLORE44\u00a0trial at 2025 MDA Clinical &amp; Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET Key opinion leaders to participate in Avidity sponsored industry forum event &#8220;Advancing RNA Therapeutics&#8221;, March 17, 2025, at 7:00 a.m. CT\/8:00 a.m. ET SAN DIEGO , March 12, 2025 \/PRNewswire\/ &#8212; Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that the company will be presenting one &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-825025","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children&#8217;s Hospital and EXPLORE44 \u00ae trial investigator, will present topline del-zota data from Phase 1\/2 EXPLORE44\u00a0trial at 2025 MDA Clinical &amp; Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET Key opinion leaders to participate in Avidity sponsored industry forum event &#8220;Advancing RNA Therapeutics&#8221;, March 17, 2025, at 7:00 a.m. CT\/8:00 a.m. ET SAN DIEGO , March 12, 2025 \/PRNewswire\/ &#8212; Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that the company will be presenting one &hellip; Continue reading &quot;Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-12T20:46:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference\",\"datePublished\":\"2025-03-12T20:46:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\"},\"wordCount\":702,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/974628\\\/Avidity_Biosciences_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\",\"name\":\"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/974628\\\/Avidity_Biosciences_Logo.jpg\",\"datePublished\":\"2025-03-12T20:46:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/974628\\\/Avidity_Biosciences_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/974628\\\/Avidity_Biosciences_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/","og_locale":"en_US","og_type":"article","og_title":"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk","og_description":"PR Newswire Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children&#8217;s Hospital and EXPLORE44 \u00ae trial investigator, will present topline del-zota data from Phase 1\/2 EXPLORE44\u00a0trial at 2025 MDA Clinical &amp; Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET Key opinion leaders to participate in Avidity sponsored industry forum event &#8220;Advancing RNA Therapeutics&#8221;, March 17, 2025, at 7:00 a.m. CT\/8:00 a.m. ET SAN DIEGO , March 12, 2025 \/PRNewswire\/ &#8212; Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs\u2122), today announced that the company will be presenting one &hellip; Continue reading \"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-12T20:46:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference","datePublished":"2025-03-12T20:46:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/"},"wordCount":702,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/","name":"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg","datePublished":"2025-03-12T20:46:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/974628\/Avidity_Biosciences_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avidity-biosciences-announces-upcoming-presentations-at-the-muscular-dystrophy-association-mda-clinical-scientific-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/825025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=825025"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/825025\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=825025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=825025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=825025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}